Innodiab expands Certania’s Life Sciences capabilities in diabetes and obesity

Munich | Essen, Germany | 22 April, 2026 — InnoDiab Forschung GmbH (“InnoDiab”), a specialised clinical research centre focused on metabolic diseases, has joined CERTANIA’s Life Sciences segment. InnoDiab supports pharmaceutical sponsors and contract research organisations (CROs) in the execution of clinical trials in diabetes, obesity and related cardiorenal indications, combining clinical expertise with efficient patient recruitment and site management.

InnoDiab, founded in 2016, is based in Essen (North Rhine–Westphalia) and operates from a dedicated clinical trial center. It benefits from direct access to a well-characterised patient population, supporting reliable recruitment for complex studies. Clinical trial projects may run from a few months to several years and include patient recruitment, study execution and site management activities.

InnoDiab strengthens CERTANIA’s Life Sciences segment through complementary clinical research capabilities and direct patient recruitment access, enabling collaboration with existing CRO partners across the group.

“InnoDiab expands our Life Sciences clinical research capabilities and strengthens our expertise in metabolic disease trials,” says Karsten Xander, CEO and founder of CERTANIA. “The combination of clinical experience and patient access in Essen is a relevant addition to our portfolio and supports our ambition to offer sponsors a broader set of capabilities across the clinical trial value chain.”

“As part of CERTANIA, we can further develop our clinical research activities while continuing to provide reliable trial execution in diabetes and obesity,” says Dr. Helga Zeller, Managing Director and founder, InnoDiab.

“The partnership creates a stronger basis for collaboration with clinical research partners and for selectively participating in studies where our experience and patient access add clear value,” adds Dr. Thomas Schürholz, Managing Director and founder, InnoDiab.

About InnoDiab: InnoDiab Forschung GmbH (“InnoDiab”) is a specialised clinical research centre based in Essen (NRW), Germany, focused on clinical trials in diabetes, obesity and related metabolic diseases. InnoDiab supports pharmaceutical and medical device sponsors as well as CROs across patient recruitment, study execution and site management. More information: www.innodiab.de

About CERTANIA: CERTANIA Group, headquartered in Munich, is an internationally active Testing, Inspection & Certification (TIC) company with centuries of combined experience. Its experts shape industry standards and continuously advance methods across life sciences, food and consumer goods, industrials, buildings and infrastructure, as well as certification and compliance. More information: www.certania.com.